OBJECTIVES: Pancreatic ductal adenocarcinoma (PDAC) has a dismal 5-year survival rate of 5%. There is an urgent need for early detection while the tumors are small and surgically resectable. We assessed serum osteopontin (OPN) and tissue inhibitor of metalloproteinase 1 (TIMP-1) as possible diagnostic and prognostic biomarkers in a novel cohort of patients with pancreatic cancer. METHODS: Osteopontin and TIMP-1 levels were determined in sera from 86 patients with PDAC, 86 healthy control subjects, and 48 patients with chronic pancreatitis. Regression models were used to relate OPN and TIMP-1 to sex, age, stage, class, and treatment. Survival analyses were performed using univariate and multivariate Cox models. RESULTS: The serum levels of both OPN and TIMP-1 distinguished PDAC from chronic pancreatitis (P ≤ 0.0001) and healthy control subjects (P < 0.0001). The serum levels of both OPN and TIMP-1 also distinguished early-stage resectable PDAC cases from chronic pancreatitis (P < 0.04) and healthy control subjects (P < 0.01). High serum levels of OPN were significantly correlated with reduced patient survival. CONCLUSIONS: Serum OPN and TIMP-1 have use as diagnostic biomarkers in PDAC. Our data suggest a potential benefit of using OPN, TIMP-1, and CA 19-9 in a panel to improve diagnostic accuracy in PDAC.
OBJECTIVES:Pancreatic ductal adenocarcinoma (PDAC) has a dismal 5-year survival rate of 5%. There is an urgent need for early detection while the tumors are small and surgically resectable. We assessed serum osteopontin (OPN) and tissue inhibitor of metalloproteinase 1 (TIMP-1) as possible diagnostic and prognostic biomarkers in a novel cohort of patients with pancreatic cancer. METHODS:Osteopontin and TIMP-1 levels were determined in sera from 86 patients with PDAC, 86 healthy control subjects, and 48 patients with chronic pancreatitis. Regression models were used to relate OPN and TIMP-1 to sex, age, stage, class, and treatment. Survival analyses were performed using univariate and multivariate Cox models. RESULTS: The serum levels of both OPN and TIMP-1 distinguished PDAC from chronic pancreatitis (P ≤ 0.0001) and healthy control subjects (P < 0.0001). The serum levels of both OPN and TIMP-1 also distinguished early-stage resectable PDAC cases from chronic pancreatitis (P < 0.04) and healthy control subjects (P < 0.01). High serum levels of OPN were significantly correlated with reduced patient survival. CONCLUSIONS: Serum OPN and TIMP-1 have use as diagnostic biomarkers in PDAC. Our data suggest a potential benefit of using OPN, TIMP-1, and CA 19-9 in a panel to improve diagnostic accuracy in PDAC.
Authors: W Zhou; L J Sokoll; D J Bruzek; L Zhang; V E Velculescu; S B Goldin; R H Hruban; S E Kern; S R Hamilton; D W Chan; B Vogelstein; K W Kinzler Journal: Cancer Epidemiol Biomarkers Prev Date: 1998-02 Impact factor: 4.254
Authors: A Kolb; J Kleeff; A Guweidhi; I Esposito; N A Giese; H Adwan; T Giese; M W Büchler; M R Berger; H Friess Journal: Cancer Biol Ther Date: 2005-07-05 Impact factor: 4.742
Authors: Rebecca L H Bigelow; Briana J Williams; Jennifer L Carroll; Lisa K Daves; James A Cardelli Journal: Breast Cancer Res Treat Date: 2008-09-12 Impact factor: 4.872
Authors: M L Davidsen; S Ø Würtz; M U Rømer; N M Sørensen; S K Johansen; I J Christensen; J K Larsen; H Offenberg; N Brünner; U Lademann Journal: Br J Cancer Date: 2006-10-23 Impact factor: 7.640
Authors: H C Harsha; Kumaran Kandasamy; Prathibha Ranganathan; Sandhya Rani; Subhashri Ramabadran; Sashikanth Gollapudi; Lavanya Balakrishnan; Sutopa B Dwivedi; Deepthi Telikicherla; Lakshmi Dhevi N Selvan; Renu Goel; Suresh Mathivanan; Arivusudar Marimuthu; Manoj Kashyap; Robert F Vizza; Robert J Mayer; James A Decaprio; Sudhir Srivastava; Samir M Hanash; Ralph H Hruban; Akhilesh Pandey Journal: PLoS Med Date: 2009-04-07 Impact factor: 11.069
Authors: Martin C Whittle; Kamel Izeradjene; P Geetha Rani; Libing Feng; Markus A Carlson; Kathleen E DelGiorno; Laura D Wood; Michael Goggins; Ralph H Hruban; Amy E Chang; Philamer Calses; Shelley M Thorsen; Sunil R Hingorani Journal: Cell Date: 2015-05-21 Impact factor: 41.582
Authors: Michela Capello; Leonidas E Bantis; Ghislaine Scelo; Yang Zhao; Peng Li; Dilsher S Dhillon; Nikul J Patel; Deepali L Kundnani; Hong Wang; James L Abbruzzese; Anirban Maitra; Margaret A Tempero; Randall Brand; Matthew A Firpo; Sean J Mulvihill; Matthew H Katz; Paul Brennan; Ziding Feng; Ayumu Taguchi; Samir M Hanash Journal: J Natl Cancer Inst Date: 2017-04-01 Impact factor: 13.506
Authors: Wilson Petrushnko; Justin S Gundara; Philip R De Reuver; Greg O'Grady; Jaswinder S Samra; Anubhav Mittal Journal: HPB (Oxford) Date: 2016-07-14 Impact factor: 3.647
Authors: Jin Song; Lori J Sokoll; Jered J Pasay; Abigail L Rubin; Hanying Li; Dylan M Bach; Daniel W Chan; Zhen Zhang Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-10-17 Impact factor: 4.254
Authors: Zachary W Kendrick; Matthew A Firpo; Robert C Repko; Courtney L Scaife; Douglas G Adler; Kenneth M Boucher; Sean J Mulvihill Journal: HPB (Oxford) Date: 2013-12-06 Impact factor: 3.647